An Overview of the Landscape Surrounding Melanoma

Now Viewing

EP: 1.An Overview of the Landscape Surrounding Melanoma

EP: 2.The Role of Biomarker Testing in Melanoma

EP: 3.The Current Landscape Surrounding Adjuvant Therapy in Melanoma

EP: 4.Combination Immunotherapy Strategies for Melanoma in the Adjuvant Setting

EP: 5.Navigating Challenges in Predicting and Mitigating Adverse Events in Adjuvant Immunotherapy

EP: 6.Exploring Immunotherapy Resistance: Impact on Treatment Decisions in Melanoma

EP: 7.Balancing Quality of Life: Adjuvant Therapy Toxicity in Melanoma Adjuvant Immunotherapy

EP: 8.Case 1: Man Aged 55 Years With Stage IIIB Melanoma Developing Immunotherapy-Induced Diabetes

EP: 9.Immunotherapy-Related Diabetes in Melanoma: A Management Perspective

EP: 10.Immunotherapy-Induced Adrenal Insufficiency in Melanoma: Surveillance and Management

EP: 11.Case 2: 63-Year-Old Female Patient With Metastatic Melanoma on Dual Immunotherapy Developing Treatment-Related Myocarditis

EP: 12.Approaches to Diagnosing and Managing Myocarditis Related to Immunotherapy

EP: 13.Expert Perspectives on Cardiac Baseline and Surveillance Testing in Immunotherapy Recipients

EP: 14.Corticosteroid Treatment Challenges in Patients with Immunotherapy-Related Toxicities

EP: 15.Forward Outlook and Clinical Insights in Melanoma Treatment

This is a video synopsis/summary of an OncLive Insights^® discussion involving Afreen Shariff, MD, MBBS; Javid Moslehi, MD; and Nikhil Khushalani, MD.

In the video, Dr Shariff introduces herself and the other panelists, Dr Moslehi and Dr Khushalani. Dr Khushalani provides an overview of melanoma treatment and epidemiology, noting that invasive melanoma incidence has been rising over the past 10 to 15 years. He states that in 2024 there will be an estimated 90,000 to 100,000 new cases of invasive melanoma, and closer to 200,000 cases when including melanoma in situ. Dr Khushalani warns that if sun exposure behaviors don’t change, melanoma could become the second most commonly diagnosed cancer in adults by 2040.

When asked about prognosis, Dr Khushalani explains it depends greatly on disease stage at diagnosis. The 5-year survival rate is over 98% for stage I, around 80% to 85% for stage II, 65% to 70% for stage III, and 30% to 35% for stage IV. He notes that stage IV survival has improved in the immune checkpoint and MAP kinase inhibitor therapy era.

Video synopsis is AI-generated and reviewed by OncLive® editorial staff.